MMS Holdings Executive and Leadership Team

Stacy Rusley, the Chief Financial Officer at MMS Holdings, directs all fiscal planning and capital allocation strategies to support global growth. Overseeing the financial health of the organization, the Chief Financial Officer ensures alignment between budgetary constraints and the science-first mission of the company. This leadership role involves managing complex revenue streams and optimizing resource distribution across international markets. By implementing rigorous financial controls, Stacy Rusley directly impacts the long-term stability of the CRO. Rusley monitors economic trends to mitigate risks while fostering organic expansion. Through precise fiscal oversight, the Chief Financial Officer enables the firm to maintain high-quality data services for sponsors. Ultimately, Rusley secures the necessary capital to sustain the 97 percent customer satisfaction rating while driving sustainable profitability across all regional operations.

Christopher Schoonmaker, the Chief Operating Officer at MMS Holdings, manages the execution of global data services and regulatory submission workflows. Overseeing the daily operations of 950 colleagues, the Chief Operating Officer ensures that every project receives the dedicated care required for positive sponsor outcomes. This leadership role involves streamlining internal processes to maintain the company's reputation for dependable, science-driven results. By integrating advanced technology into clinical workflows, Christopher Schoonmaker directly improves operational efficiency across North American and international sites. Schoonmaker coordinates with cross-functional teams to scale service delivery in response to changing sponsor needs. Through consistent process refinement, the Chief Operating Officer supports the firm's organic growth trajectory. Ultimately, Schoonmaker maintains the high standards of excellence that define the organization's approach to complex regulatory challenges.

Micky Miranda, the President at MMS Holdings, architects the overarching corporate strategy and long-term vision for the global CRO. Overseeing the expansion of service offerings, the President ensures that the company remains a leader in data-focused clinical research. This leadership role involves cultivating high-level partnerships with sponsors to address evolving regulatory requirements. By driving innovation in clinical data management, Micky Miranda directly influences the firm's market position and competitive advantage. Miranda fosters a culture of accountability and scientific rigor among the global workforce. Through strategic oversight of business development initiatives, the President accelerates the company's reach into new therapeutic areas. Ultimately, Miranda guides the organization toward sustained success by prioritizing client-centric solutions and maintaining the integrity of the firm's proven regulatory submission processes.

Yonghoon Jeong, the President at MMS Holdings, directs the implementation of specialized clinical research initiatives and regional market penetration strategies. Overseeing the integration of data-focused methodologies, the President ensures that the firm delivers consistent value to sponsors navigating complex regulatory landscapes. This leadership role involves managing the alignment of technical expertise with client-specific project goals. By optimizing the delivery of clinical services, Yonghoon Jeong directly contributes to the company's reputation for excellence and reliability. Jeong coordinates with internal stakeholders to enhance the quality of regulatory submissions across diverse global markets. Through the application of rigorous scientific standards, the President supports the firm's commitment to positive outcomes. Ultimately, Jeong drives operational excellence by fostering deep collaboration between the company's 950 colleagues and the sponsors relying on these critical data services.